TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BRIEF-A Global Executive Composite score (GEC) ≥ 65, or Behavioral Regulation Index score (BRI) ≥ 65, or Metacognition Index score (MI) ≥ 65.~* Subjects must meet consensus criteria for chronic fatigue syndrome.~* Provide written informed consent for participation in the trial before completing any study-related procedures.~* 18-60 years at time of consent~* Male or non-pregnant females who are not breastfeeding.~* Females of reproductive potential must agree to use a medically accepted means of contraception when engaging in sexual intercourse at any time during the study.~* Are able to swallow study medication.~Exclusion Criteria:~* CFS and executive functioning impairment are not present or not diagnosable~* Serious comorbid psychiatric condition~* Subjects who were pregnant, nursing, or intended to become pregnant~* Subjects who had been on a psychostimulant regimen in the last six months~* Subjects who had a medical condition that would have been affected by psychostimulant medication~* Subjects who were of low intelligence, or who were unable to communicate effectively with the study team

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Lisdexamfetamine Dimesylate (Type: ACTIVE_COMPARATOR): Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
- Sugar pill (Type: PLACEBO_COMPARATOR): Matching Placebo 30, 50 or 70 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant female subjects (40 years of age and older).~* Patients with diagnosis of COPD according to the GOLD guidelines.~* Post-bronchodilator FEV1 \<80% of the predicted value at the screening visit.~* Post-bronchodilator FEV1/FVC ratio ≤0.70 at the screening visit.~* Current or former smokers (e.g., with history of = 10 pack-years).~* Written informed consent.~Exclusion Criteria:~* Known respiratory disorder other than COPD including, but not limited to the following: alpha-1 antitrypsin deficiency, cystic fibrosis, significant asthma, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease.~* History of allergy or hypersensitivity to anticholinergic/muscarinic receptor antagonist agents, beta-2 adrenergic agonists, lactose/milk proteins, or known hypersensitivity to any of the proposed ingredients or components of the delivery system.~* Hospitalization for COPD or pneumonia within 12 weeks prior to the screening visit.~* Treatment for COPD exacerbation within 12 weeks prior to the screening visit.~* Viral or bacterial upper or lower respiratory tract infection, sinusitis, sinus infection, rhinitis, pharyngitis, middle ear infection, urinary tract infection, or illness within 6 weeks prior to the screening visit.~* Abnormal and significant ECG finding prior to the screening, during the run-in and treatment periods.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test Product (tiotropium bromide inhalation powder) (Type: EXPERIMENTAL): Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness).
- Reference Product (Spiriva®) (Type: ACTIVE_COMPARATOR): Single dose of reference product (Spiriva®) 18 mcg
- Placebo (Type: PLACEBO_COMPARATOR): Single dose of placebo inhalation powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)~* At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening)~* Neurologic stability for greater than or equal to (\>=) 30 days prior to both screening and baseline~* Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive~Exclusion Criteria:~* Primary progressive multiple sclerosis~* Disease duration of more than 10 years in participants with EDSS less than or equal to (\<=) 2.0 at screening~* Contraindications for MRI~* Known presence of other neurological disorders which may mimic multiple sclerosis~* Pregnancy or lactation~* Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study~* History of or currently active primary or secondary immunodeficiency~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies~* Active infection, or history of or known presence of recurrent or chronic infection (e.g., hepatitis B or C, human immunodeficiency virus \[HIV\], syphilis, tuberculosis)~* History of progressive multifocal leukoencephalopathy~* Contraindications to or intolerance of oral or iv corticosteroids~* Contraindications to Rebif or incompatibility with Rebif use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Interferon beta-1a 44 mcg SC (Type: ACTIVE_COMPARATOR): Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
- Ocrelizumab (Type: EXPERIMENTAL): Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants below 3 months of age ( corrected age 54 weeks) presenting for elective inguinal hernia repair in KKH.~Exclusion Criteria:~* History of prematurity younger than 28 weeks gestation,~* Requirement for CPAP greater than 6 cmH20 at time of surgery~* Significant cardiac pathology or cardiac conduction defects~* Unusually large hernia sacs~* Any contraindication for caudal anesthesia~* Surgeon refusal on account of anticipated prolonged or difficult surgery.

- Gender: ALL
- Minimum Age: 34 Weeks
- Maximum Age: 54 Weeks
- Healthy Volunteers: t

Study Arms:
- Dex Group (Type: EXPERIMENTAL): Intravenous dexmedetomidine sedation prior to single shot caudal anaesthesia and maintenance infusion of dexmedetomidine during bilateral inguinal hernia surgery.
- GA Group (Type: ACTIVE_COMPARATOR): General sevoflurane anaesthesia with endotracheal intubation and single shot caudal anaesthesia for inguinal hernia surgery. This is currently the standard anaesthetic technique for bilateral inguinal hernia surgery in neonates and infants in KKH.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients at least 18 years old with severe or moderately severe hemophilia A (facto VIII concentration less than or equal to 2%).~* Negative test for facto VIII inhibitor.~* If applicable, HIV or hepatitis treatment is stable at the time of enrollment.~* Ability to abstain from use of FVIII products for 72 hours at a time.~Exclusion Criteria:~* History of any positive test result for factor VIII inhibitor.~* Presence of any bleeding disorder in addition to Hemophilia A.~* Body weight less than 50 kg.~* History of alcoholism.~* Treatment with investigational drug or device within 30 days prior to the Screening visit.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
- Sequence 2 (Type: EXPERIMENTAL): Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or over~* Moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on Facial Wrinkle Scale as assessed by investigator's rating: 0= 'none', 1= 'mild', 2= 'moderate', 3= 'severe')~* Moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on Facial Wrinkle Scale as assessed by patient's assessment: 0= 'none', 1= 'mild', 2= 'moderate', 3= 'severe')~* Stable medical condition~Exclusion Criteria:~* Previous treatment with Botulinum toxin of any serotype in the glabellar area within the last 8 month~* Previous treatment with any facial aesthetic procedure (e.g. injection with biodegradable fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 month~* Previous insertion of permanent material in the glabellar area (regardless of the time between previous treatment and this study)~* Planned treatment with Botulinum toxin of any serotype in any other body region during the study period~* Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area and the surrounding areas (including eye brow)~* Any other planned facial aesthetic procedure during the trial period~* Inability to substantially lessen glabellar frown lines even by physically spreading them apart~* Marked facial asymmetry or ptosis of eyelid and/or eyebrow~* History of facial nerve palsy~* Any infection in the area of the injection sites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) (20 Units) (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with symptomatic severe heart failure with reduced ejection fraction (LVEF ≤40%,)~* Age \> 20 years~* Consent capacity~* Sinus rhythm~* Suitable for a drug conversion from AT1/ACE inhibitors to sacubitril/ valsartan~Exclusion Criteria:~* Age \< 18 years~* Atrial fibrillation~* Pregnancy~* Lack of consent capacity~* Contraindications for a therapy with sacubitril/ valsartan

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed consent. - HbA1c (glycosylated haemoglobin) 7.0 - 10.5% (53 - 91 mmol/mol) (both inclusive) - Subjects on stable diabetes treatment with metformin (minimum of 1500 mg/day or maximal tolerated dose documented in the patient medical record) for 90 days prior to screening Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) - Any condition, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term insulin treatment for acute illness for a total of equal to or below 14 days - History of pancreatitis (acute or chronic) - Screening calcitonin equal to or above 50 ng/L - Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma - Renal impairment defined as eGFR (electronic case report form) below 60 mL/min/1.73 m\^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) - Subjects presently classified as being in New York Heart Association Class IV - Planned coronary, carotid or peripheral artery revascularisation on the day of screening - Proliferative retinopathy or maculopathy requiring acute treatment - History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and in-situ carcinomas) - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days or on a frequent basis) known to affect weight or glucose metabolism (e.g. orlistat, thyroid hormones, corticosteroids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 0.5 mg/Week (Type: EXPERIMENTAL): None
- Semaglutide 1.0 mg/Week (Type: EXPERIMENTAL): None
- Dulaglutide 0.75 mg/Week (Type: ACTIVE_COMPARATOR): None
- Dulaglutide 1.5 mg/Week (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane Associated With Oral Midazolam and Ketamine for Dental Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children ASA I or II;~* Need for restorative procedure on at least one deciduous tooth below;~* Airway patent and effective nasal breathing;~* Behavior not collaborator in previous dental treatment.~Exclusion Criteria:~* Previous experience of dental treatment under sedation;~* Have completed seven years during the data collection.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam and Ketamine (Type: ACTIVE_COMPARATOR): In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
- Midazolam, Ketamine and Sevoflurane (Type: EXPERIMENTAL): In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). After fifteen minutes of this drug administration, the investigators start to provide sevoflurane, through a nasal hood, in an initial concentration of 0.1%, with 0.1% increment every 30 seconds, until a final expired concentration between 0.3 and 0.4%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare Propofol to Fentanyl and Midazolam for Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Elective outpatient colonoscopy~* American Society of Anesthesiology Class (ASA) \< IV~Exclusion Criteria:~* Age \< 18~* Inpatient status~* Emergency procedure~* History of colonic or rectal resection~* History of hypersensitivity to Propofol (or soy or egg products),Fentanyl or Midazolam~* ASA of IV~* Neurological deficit~* Acute gastrointestinal bleeding~* On anticoagulation agents~* Noncompliance with bowel regiment~* Pregnant women~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fentanyl and Midazolam (Type: ACTIVE_COMPARATOR): Fentanyl and Midazolam sedation for colonoscopy discomfort
- Propofol (Type: ACTIVE_COMPARATOR): Propofol sedation for colonoscopy discomfort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent and be able to comply with all study requirements~* Healthy males or females aged 18-65 inclusive~* Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal~* Males must be surgically sterile, abstinent or using an acceptable contraceptive method~* BMI \< 35.0 kg/m2~* Subjects must have Fasting TG ≥ 90 mg/dL or ≥ 200 mg/dL depending on Cohort assignment~Exclusion Criteria:~* Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B~* Treatment with another Study Drug, biological agent, or device within one-month of screening~* Regular excessive use of alcohol within 6 months of Screening~* Use of concomitant drugs unless authorized by the Sponsor Medical Monitor~* Smoking \> 10 cigarettes a day~* Considered unsuitable for inclusion by the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- IONIS-APOC-III-LRx (Type: EXPERIMENTAL): Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
- Placebo (Normal Saline) (Type: PLACEBO_COMPARATOR): Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine if the Midazolam-Meperidine-Dexmedetomidine is Superior to the Midazolam-Meperidine for Sedation During ERCP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who are admitted for diagnostic and therapeutic ERCPs~* aged 20 to 80 years~* American Society of Anesthesiologists (ASA) classification I to III~Exclusion Criteria:~* ASA physical status IV and V~* allergic to any components of sedation and opioid drugs~* patients with chronic illicit drug use

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam-Meperidine-Dexmedetomidine (Type: EXPERIMENTAL): midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
- Midazolam-Meperidine (Type: SHAM_COMPARATOR): midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete